TVTX
Travere Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$55.47-2.19%
Price as of Jul 20, 2026
TVTX financials
Travere Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $490.7M | $233.2M | $145.2M | $109.5M |
| Cost of revenue | $10.3M | $7.7M | $11.4M | $4.4M |
| Gross profit | $480.4M | $225.4M | $133.8M | $105.0M |
| Operating expenses | $543.2M | $549.3M | $521.9M | $424.9M |
| Operating income | -$62.8M | -$323.8M | -$388.1M | -$319.8M |
| Net income | -$25.5M | -$321.5M | -$111.4M | -$278.5M |
| EBITDA | $22.2M | -$265.8M | -$326.2M | -$299.4M |
| Basic EPS | $-0.56 | $-4.08 | $-1.50 | $-4.37 |
| Diluted EPS | $-0.56 | $-4.08 | $-1.50 | $-4.37 |
| Balance sheet | ||||
| Cash & equivalents | $93.0M | $58.5M | $58.2M | $61.7M |
| Total assets | $605.2M | $594.1M | $788.9M | $672.6M |
| Total liabilities | $490.4M | $535.0M | $588.1M | $629.7M |
| Stockholders’ equity | $114.8M | $59.1M | $200.8M | $42.9M |
| Total debt | $328.7M | $401.6M | $404.8M | $407.5M |
| Net debt | $235.7M | $343.0M | $346.6M | $345.8M |
| Cash flow | ||||
| Operating cash flow | $37.8M | -$237.5M | -$280.0M | -$186.3M |
| Capital expenditure | -$58.2M | -$101.2M | -$41.6M | -$28.4M |
| Free cash flow | -$20.4M | -$338.7M | -$321.6M | -$214.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |